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Losinger's criticism of our paper pertains to the following key points: the 
use of national estimates, the functional form employed, making multiple 
uses of the model, not considering all the costs, and the use of NAHMS 
data for economic analysis. We briefly address each one below, beginning 
with the last: 
 
The use of NAHMS data for economic analysis was done as we outlined 
in the paper by progressing from the physical relationships to the 
economic. Current NAHMS national studies, including Dairy '96, collect 
little economic information. However, productivity parameters, such as 
milk production per cow, can be collected and used to estimate the 
association between disease and productivity. Changes in gross revenue 
can then be determined by multiplying the output prices by the estimated 
productivity changes. 
 
As suggested, we did not collect complete production cost data, thus (as 
stated in the paper) we relied on the cost estimates of others. 
 
Why use a similar model multiple times? The first model mentioned in the 
commentary was developed to determine economic impact associated 
with Johne's disease. Several parameters can affect productivity at the 
herd level, the level at which NAHMS data is collected. Thus, the model 
included parameters other than Johne's disease that are associated with 
herd level milk production per cow. Among the included parameters were 
bulk tank somatic cell count (BTSCC) and rBST use. 
 
In modeling milk response to rBST use, inspection of plotted data points 
did not reveal any particular functional form. The square root function was 
chosen due to a slightly higher R-square than the quadratic. While the Ott-
Novak manuscript and our manuscript could have been written from this 
model, they were not, as the Johne's disease variable reduced the number 
of observations by approximately 20 percent. Accordingly, in the revised 
specification we dropped the Johne's disease variable and increased the  
sample size. Analysis for the Ott-Novak manuscript was done first and no 
further investigation of rBST was done for that manuscript. 
 
It is not the "tweaking" of the model that gives rise to multiple publications, 
but the subject matter covered. The difference in impact associated with 
BTSCC between the Ott-Novak and Ott-Rendleman publications is less 
than one percent. Their true differences are in the variables of interest: 
rBST vs. BTSCC, and thus both make contributions to the literature. 
 
It should be noted that the first draft of the article included both quadratic 
and square root functional forms for rBST. The final version of the article 
accepted by AgBioForum for publication included only the quadratic form. 
This was because brevity was requested and because the associated 
marginal product is linear. 
 
One concern the commentator had with the quadratic function form 
equation was the decline in milk production when rBST use exceeds 87 
percent. When rBST use is divided into 10 percent intervals with 0 and 
100 percent as separate categories the 60-69 percent category had the 
highest milk production per cow. Thus, very high levels of rBST use have 
marginal physical product very close to zero as did our model. While it is 
indeed unlikely that rBST use beyond 87 percent would depress milk 
production it makes no serious difference in this case. Whether the milk 
response is estimated using a quadratic equation or a square-root 
equation, the conclusions remain the same: that rBST use does increase 
milk production and is profitable to use; that producers should be checking 
individual cow response as some cows may have limited-unprofitable 
response; and that with rBST being profitable its use most likely will 
increase and thus the need to have fewer cows and therefore fewer dairy 
producers to produce a given quantity of milk. 
 
Regarding the use of national estimates, Losinger is technically correct. In 
practice however, this is an insignificant issue. NAHMS studies are 
designed to represent at least 80 percent of the national population. To be 
statistically correct, instead of multiplying by all the cows in the country to 
determine national impact we should multiply by 83 percent of the cows to 
make an estimate for these cows and leave the reader to guess what the 
national impact would be from the remaining 17 percent of cows. Most 
likely the reader would assume the same per cow effect and thus obtain 
the same national impact as the one we provided. 
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